Which has better valuation and earnings, COAG or TWST?

Hemab Therapeutics has higher earnings, but lower revenue than Twist Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Twist Bioscience $376.57M 17.01 -$77.67M -$1.33 N/A

Does the media favor COAG or TWST?

In the previous week, Twist Bioscience had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 13 mentions for Twist Bioscience and 4 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.38 beat Twist Bioscience's score of 0.22 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, COAG or CGON?

Hemab Therapeutics has higher earnings, but lower revenue than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A CG Oncology $5.07M 1,235.80 -$160.99M -$2.33 N/A

Is COAG or CGON more profitable?

Hemab Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A CG Oncology N/A -23.33% -22.24%

Does the media favor COAG or CGON?

In the previous week, CG Oncology had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 13 mentions for CG Oncology and 4 mentions for Hemab Therapeutics. CG Oncology's average media sentiment score of 0.63 beat Hemab Therapeutics' score of 0.38 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, COAG or CRSP?

Hemab Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A CRISPR Therapeutics $3.51M 1,499.92 -$581.60M -$6.22 N/A

Does the media prefer COAG or CRSP?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 4 mentions for Hemab Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Hemab Therapeutics' score of 0.38 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LEGN or COAG?

Hemab Therapeutics has lower revenue, but higher earnings than Legend Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Legend Biotech $1.14B 4.71 -$296.80M -$0.68 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Does the media refer more to LEGN or COAG?

In the previous week, Hemab Therapeutics had 1 more articles in the media than Legend Biotech. MarketBeat recorded 4 mentions for Hemab Therapeutics and 3 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.94 beat Hemab Therapeutics' score of 0.38 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, AMRX or COAG?

Amneal Pharmaceuticals has higher revenue and earnings than Hemab Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amneal Pharmaceuticals $3.02B 1.83 $72.06M $0.38 45.55 Hemab Therapeutics N/A N/A N/A N/A N/A

Does the media favor AMRX or COAG?

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 4 mentions for Hemab Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat Hemab Therapeutics' score of 0.38 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hemab Therapeutics (COAG) Competitors

$36.73 0.00 (0.00%)

As of 04:00 PM Eastern

Compare

COAG vs. TWST, CGON, CRSP, LEGN, and AMRX

Should you buy Hemab Therapeutics stock or one of its competitors? MarketBeat compares Hemab Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemab Therapeutics include Twist Bioscience (TWST), CG Oncology (CGON), CRISPR Therapeutics (CRSP), Legend Biotech (LEGN), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Hemab Therapeutics compare to Twist Bioscience?

Hemab Therapeutics (NASDAQ:COAG) and Twist Bioscience (NASDAQ:TWST) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Hemab Therapeutics has higher earnings, but lower revenue than Twist Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Twist Bioscience	$376.57M	17.01	-$77.67M	-$1.33	N/A

In the previous week, Twist Bioscience had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 13 mentions for Twist Bioscience and 4 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.38 beat Twist Bioscience's score of 0.22 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics currently has a consensus target price of $41.40, indicating a potential upside of 12.71%. Twist Bioscience has a consensus target price of $79.30, indicating a potential downside of 22.92%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Hemab Therapeutics has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Hemab Therapeutics' return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Twist Bioscience	-19.85%	-26.73%	-19.15%

Summary

Hemab Therapeutics beats Twist Bioscience on 6 of the 9 factors compared between the two stocks.

How does Hemab Therapeutics compare to CG Oncology?

Hemab Therapeutics (NASDAQ:COAG) and CG Oncology (NASDAQ:CGON) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Hemab Therapeutics has higher earnings, but lower revenue than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
CG Oncology	$5.07M	1,235.80	-$160.99M	-$2.33	N/A

Hemab Therapeutics presently has a consensus price target of $41.40, suggesting a potential upside of 12.71%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 15.03%. Given CG Oncology's higher possible upside, analysts clearly believe CG Oncology is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, CG Oncology had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 13 mentions for CG Oncology and 4 mentions for Hemab Therapeutics. CG Oncology's average media sentiment score of 0.63 beat Hemab Therapeutics' score of 0.38 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
CG Oncology	N/A	-23.33%	-22.24%

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CG Oncology beats Hemab Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Hemab Therapeutics compare to CRISPR Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and CRISPR Therapeutics (NASDAQ:CRSP) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Hemab Therapeutics currently has a consensus target price of $41.40, suggesting a potential upside of 12.71%. CRISPR Therapeutics has a consensus target price of $67.78, suggesting a potential upside of 24.17%. Given CRISPR Therapeutics' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Hemab Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. Hemab Therapeutics' return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hemab Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
CRISPR Therapeutics	$3.51M	1,499.92	-$581.60M	-$6.22	N/A

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 4 mentions for Hemab Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Hemab Therapeutics' score of 0.38 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CRISPR Therapeutics beats Hemab Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Hemab Therapeutics (NASDAQ:COAG) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Legend Biotech currently has a consensus price target of $60.23, indicating a potential upside of 108.56%. Hemab Therapeutics has a consensus price target of $41.40, indicating a potential upside of 12.71%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Hemab Therapeutics has lower revenue, but higher earnings than Legend Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.14B	4.71	-$296.80M	-$0.68	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Hemab Therapeutics' return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Hemab Therapeutics	N/A	N/A	N/A

In the previous week, Hemab Therapeutics had 1 more articles in the media than Legend Biotech. MarketBeat recorded 4 mentions for Hemab Therapeutics and 3 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.94 beat Hemab Therapeutics' score of 0.38 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Legend Biotech beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Hemab Therapeutics compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Hemab Therapeutics (NASDAQ:COAG) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amneal Pharmaceuticals currently has a consensus price target of $15.80, indicating a potential downside of 8.72%. Hemab Therapeutics has a consensus price target of $41.40, indicating a potential upside of 12.71%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Amneal Pharmaceuticals has higher revenue and earnings than Hemab Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.83	$72.06M	$0.38	45.55
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 4 mentions for Hemab Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat Hemab Therapeutics' score of 0.38 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has a net margin of 4.01% compared to Hemab Therapeutics' net margin of 0.00%. Hemab Therapeutics' return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Hemab Therapeutics	N/A	N/A	N/A

Summary

Amneal Pharmaceuticals beats Hemab Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Hemab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COAG vs. The Competition

Export

Metric	Hemab Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.72B	$557.11M	$4.47B	$12.60B
Dividend Yield	N/A	N/A	13.72%	6.21%
P/E Ratio	N/A	N/A	23.52	24.88
Price / Sales	N/A	74.90	153.19	115.95
Price / Cash	N/A	N/A	36.62	36.96
Price / Book	N/A	2.96	13.36	6.56
Net Income	N/A	-$81.71M	$114.87M	$336.70M
7 Day Performance	26.00%	12.34%	0.99%	3.31%
1 Month Performance	28.88%	6.81%	0.72%	1.68%
1 Year Performance	N/A	-71.09%	12.54%	31.96%

Hemab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COAG Hemab Therapeutics	3.9111 of 5 stars	$36.73 flat	$41.40 +12.7%	N/A	$1.72B	N/A	N/A	72
TWST Twist Bioscience	1.391 of 5 stars	$87.56 flat	$71.60 -18.2%	+173.8%	$5.45B	$376.57M	N/A	990	Analyst Forecast High Trading Volume
CGON CG Oncology	2.8361 of 5 stars	$61.08 flat	$81.73 +33.8%	+184.1%	$5.39B	$4.04M	N/A	61	News Coverage Insider Trade Options Volume High Trading Volume
CRSP CRISPR Therapeutics	2.5889 of 5 stars	$54.09 flat	$67.78 +25.3%	+18.7%	$5.22B	$3.51M	N/A	460	Analyst Upgrade
LEGN Legend Biotech	4.2219 of 5 stars	$27.93 flat	$60.23 +115.6%	-15.1%	$5.19B	$1.03B	N/A	2,965	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COAG) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemab Therapeutics (COAG) Competitors

COAG vs. TWST, CGON, CRSP, LEGN, and AMRX

How does Hemab Therapeutics compare to Twist Bioscience?

Summary

How does Hemab Therapeutics compare to CG Oncology?

Summary

How does Hemab Therapeutics compare to CRISPR Therapeutics?

Summary

How does Hemab Therapeutics compare to Legend Biotech?

Summary

How does Hemab Therapeutics compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemab Therapeutics (COAG) Competitors

COAG vs. TWST, CGON, CRSP, LEGN, and AMRX

How does Hemab Therapeutics compare to Twist Bioscience?

Which has better valuation and earnings, COAG or TWST?

Does the media favor COAG or TWST?

Do analysts rate COAG or TWST?

Is COAG or TWST more profitable?

Summary

How does Hemab Therapeutics compare to CG Oncology?

Which has preferable valuation and earnings, COAG or CGON?

Do analysts recommend COAG or CGON?

Does the media favor COAG or CGON?

Is COAG or CGON more profitable?

Do insiders and institutionals hold more shares of COAG or CGON?

Summary

How does Hemab Therapeutics compare to CRISPR Therapeutics?

Do analysts recommend COAG or CRSP?

Is COAG or CRSP more profitable?

Do insiders & institutionals hold more shares of COAG or CRSP?

Which has stronger earnings & valuation, COAG or CRSP?

Does the media prefer COAG or CRSP?

Summary

How does Hemab Therapeutics compare to Legend Biotech?

Do analysts recommend LEGN or COAG?

Which has preferable valuation & earnings, LEGN or COAG?

Is LEGN or COAG more profitable?

Does the media refer more to LEGN or COAG?

Do insiders and institutionals have more ownership in LEGN or COAG?

Summary

How does Hemab Therapeutics compare to Amneal Pharmaceuticals?

Do insiders & institutionals have more ownership in AMRX or COAG?

Do analysts recommend AMRX or COAG?

Which has preferable valuation & earnings, AMRX or COAG?

Does the media favor AMRX or COAG?

Is AMRX or COAG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools